Skip to content

Study · Systematic review · 2024

6 results

Clinical Efficacy and Safety of Anti-Obesity Medications Among Adult East Asian People with Obesity: A Systematic Literature Review and Indirect Treatment Comparison.

Yokote K, Ota R, Wada S, Matsuda H, Filomeno R

Advances in therapy22 Jul 2024Cited by 3 (Europe PMC)

PMID39039386 (opens in a new tab)PMCIDPMC11349800 (opens in a new tab)DOI10.1007/s12325-024-02941-7 (opens in a new tab)PepBankPUB-39039386
Read at sourcePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In Japanese and South Korean people with obesity, the STEP 6 trial showed subcutaneous semaglutide reduced body weight versus placebo.

    In plain wordsIn Japanese and South Korean people with obesity, semaglutide injections led to more weight loss than placebo.

    Peptide
    Semaglutide
    Outcome
    DecreaseBody weight reduction
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    The STEP 6 study established the clinical efficacy of subcutaneous semaglutide compared with placebo in the reduction of body weight and cardiometabolic risk factors [glycated hemoglobin (HbA1c), total cholesterol, and systolic blood pressure] among Japanese and South Korean people with obesity disease.
    2 context sentences
    Summary · context
    The Embase, MEDLINE, and ICHUSHI databases were searched via the Ovid SP platform for randomized controlled trials, in English or Japanese, reporting data on semaglutide or mazindol therapy with placebo or diet and exercise as comparators.
    Summary · context
    Of 21 publications, 2 were included in this study based on the eligibility criteria.
  2. 02HumanSystematic reviewEfficacy outcome

    In Japanese and South Korean people with obesity, the STEP 6 trial showed subcutaneous semaglutide reduced HbA1c versus placebo.

    In plain wordsIn Japanese and South Korean people with obesity, semaglutide injections lowered HbA1c more than placebo.

    Peptide
    Semaglutide
    Outcome
    DecreaseHbA1c reduction
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    The STEP 6 study established the clinical efficacy of subcutaneous semaglutide compared with placebo in the reduction of body weight and cardiometabolic risk factors [glycated hemoglobin (HbA1c), total cholesterol, and systolic blood pressure] among Japanese and South Korean people with obesity disease.
    2 context sentences
    Summary · context
    The Embase, MEDLINE, and ICHUSHI databases were searched via the Ovid SP platform for randomized controlled trials, in English or Japanese, reporting data on semaglutide or mazindol therapy with placebo or diet and exercise as comparators.
    Summary · context
    Of 21 publications, 2 were included in this study based on the eligibility criteria.
  3. 03HumanSystematic reviewEfficacy outcome

    In Japanese and South Korean people with obesity, the STEP 6 trial showed subcutaneous semaglutide reduced total cholesterol versus placebo.

    In plain wordsIn Japanese and South Korean people with obesity, semaglutide injections lowered total cholesterol more than placebo.

    Peptide
    Semaglutide
    Outcome
    DecreaseTotal cholesterol reduction
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Lipids · Cardiovascular
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    The STEP 6 study established the clinical efficacy of subcutaneous semaglutide compared with placebo in the reduction of body weight and cardiometabolic risk factors [glycated hemoglobin (HbA1c), total cholesterol, and systolic blood pressure] among Japanese and South Korean people with obesity disease.
    2 context sentences
    Summary · context
    The Embase, MEDLINE, and ICHUSHI databases were searched via the Ovid SP platform for randomized controlled trials, in English or Japanese, reporting data on semaglutide or mazindol therapy with placebo or diet and exercise as comparators.
    Summary · context
    Of 21 publications, 2 were included in this study based on the eligibility criteria.
  4. 04HumanSystematic reviewEfficacy outcome

    In Japanese and South Korean people with obesity, the STEP 6 trial showed subcutaneous semaglutide reduced systolic blood pressure versus placebo.

    In plain wordsIn Japanese and South Korean people with obesity, semaglutide injections lowered systolic blood pressure more than placebo.

    Peptide
    Semaglutide
    Outcome
    DecreaseSystolic blood pressure reduction
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    The STEP 6 study established the clinical efficacy of subcutaneous semaglutide compared with placebo in the reduction of body weight and cardiometabolic risk factors [glycated hemoglobin (HbA1c), total cholesterol, and systolic blood pressure] among Japanese and South Korean people with obesity disease.
    2 context sentences
    Summary · context
    The Embase, MEDLINE, and ICHUSHI databases were searched via the Ovid SP platform for randomized controlled trials, in English or Japanese, reporting data on semaglutide or mazindol therapy with placebo or diet and exercise as comparators.
    Summary · context
    Of 21 publications, 2 were included in this study based on the eligibility criteria.
  5. 05HumanSystematic reviewSafety outcome

    In East Asian adults with obesity, semaglutide was associated with higher rates of adverse events than placebo.

    In plain wordsIn East Asian adults with obesity, semaglutide was linked to more side effects than placebo.

    Peptide
    Semaglutide
    Outcome
    IncreaseAdverse event rates
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Both semaglutide and mazindol were associated with higher rates of adverse events and treatment discontinuation than placebo.
    2 context sentences
    Summary · context
    The Embase, MEDLINE, and ICHUSHI databases were searched via the Ovid SP platform for randomized controlled trials, in English or Japanese, reporting data on semaglutide or mazindol therapy with placebo or diet and exercise as comparators.
    Summary · context
    Of 21 publications, 2 were included in this study based on the eligibility criteria.
  6. 06HumanSystematic reviewSafety outcome

    In East Asian adults with obesity, semaglutide was associated with higher rates of treatment discontinuation than placebo.

    In plain wordsIn East Asian adults with obesity, more people stopped semaglutide than stopped placebo.

    Peptide
    Semaglutide
    Outcome
    IncreaseTreatment discontinuation rates
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Both semaglutide and mazindol were associated with higher rates of adverse events and treatment discontinuation than placebo.
    2 context sentences
    Summary · context
    The Embase, MEDLINE, and ICHUSHI databases were searched via the Ovid SP platform for randomized controlled trials, in English or Japanese, reporting data on semaglutide or mazindol therapy with placebo or diet and exercise as comparators.
    Summary · context
    Of 21 publications, 2 were included in this study based on the eligibility criteria.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.